Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Transitional Cell 14Urinary Bladder Neoplasms 13Colorectal Neoplasms 10Carcinoma, Merkel Cell 9Breast Neoplasms 9Carcinoma, Renal Cell 7Neoplasms 6Neoplasm Metastasis 6Carcinoma, Non-Small-Cell Lung 6Small Cell Lung Carcinoma 4Carcinoma, Hepatocellular 4Turcot syndrome 3Stomach Neoplasms 3Neuroendocrine Tumors 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Penile Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2Lung Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Neuroendocrine 2Uterine Cervical Neoplasms 1

Interventions

Sunitinib 5pembrolizumab 4Paclitaxel 4Carboplatin 4Radiotherapy 3Cyclophosphamide 3Cisplatin 3selinexor 2lenvatinib 2Taxes 2Ramucirumab 2Octreotide 2N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2Methylprednisolone 2Erlotinib Hydrochloride 2Chemoradiotherapy 2zimberelimab 1saracatinib 1regorafenib 1epacadostat 1envafolimab 1belinostat 1avelumab 1atezolizumab 1amrubicin 1alovudine 1TP protocol 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thymoma × avelumab × Clear all
NCT03076554 2026-05-29

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
56 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡